196 related articles for article (PubMed ID: 32395166)
1. Preliminary Findings of a Dedicated Ocular Myasthenia Gravis Rating Scale: The OMGRate.
Wong SH; Eggenberger E; Cornblath W; Xhepa A; Miranda E; Lee H; Burke A; Barnett C
Neuroophthalmology; 2020 Jun; 44(3):148-156. PubMed ID: 32395166
[TBL] [Abstract][Full Text] [Related]
2. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Italian version of the Myasthenia Gravis Impairment Index (MGII).
Pasqualin F; Barnett C; Guidoni SV; Albertini E; Ermani M; Bonifati DM
Neurol Sci; 2022 Mar; 43(3):2059-2064. PubMed ID: 34505205
[TBL] [Abstract][Full Text] [Related]
4. Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
Gratton SM; Herro AM; Feuer WJ; Lam BL
J Neuroophthalmol; 2016 Mar; 36(1):37-40. PubMed ID: 26457691
[TBL] [Abstract][Full Text] [Related]
5. Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic.
Kısabay A; Özdemir HN; Gökçay F; Çelebisoy N
Acta Neurol Belg; 2022 Apr; 122(2):337-344. PubMed ID: 33544334
[TBL] [Abstract][Full Text] [Related]
6. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
[TBL] [Abstract][Full Text] [Related]
7. The MG Composite: A valid and reliable outcome measure for myasthenia gravis.
Burns TM; Conaway M; Sanders DB;
Neurology; 2010 May; 74(18):1434-40. PubMed ID: 20439845
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
[TBL] [Abstract][Full Text] [Related]
9. Reliability and Validity of Turkish Myasthenia Gravis-Activities of Daily Living Scale.
Karanfil E; Salcı Y; Fil-Balkan A; Bekircan-Kurt CE; Erdem Özdamar S; Armutlu K
OTJR (Thorofare N J); 2021 Apr; 41(2):101-107. PubMed ID: 33016212
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of the Myasthenia Gravis Impairment Index.
Barnett C; Bril V; Kapral M; Kulkarni A; Davis AM
Neurology; 2016 Aug; 87(9):879-86. PubMed ID: 27402891
[TBL] [Abstract][Full Text] [Related]
11. Validation of the Besta Neurological Institute rating scale for myasthenia gravis.
Antozzi C; Brenna G; Baggi F; Camera G; Maggi L; Rezzani C; Montomoli C; Mantegazza R
Muscle Nerve; 2016 Jan; 53(1):32-7. PubMed ID: 26372817
[TBL] [Abstract][Full Text] [Related]
12. Response to treatment in pediatric ocular myasthenia gravis.
Xu L; Castro D; Reisch JS; Iannaccone ST
Muscle Nerve; 2020 Feb; 61(2):226-230. PubMed ID: 31650555
[TBL] [Abstract][Full Text] [Related]
13. Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness.
de Meel RHP; Barnett C; Bril V; Tannemaat MR; Verschuuren JJGM
J Neuromuscul Dis; 2020; 7(3):297-300. PubMed ID: 32250313
[TBL] [Abstract][Full Text] [Related]
14. Reduced quality of life in myasthenia gravis patients: A study on 185 patients from China.
Wu X; Li RY; Ye XB; Wang N
Front Neurol; 2022; 13():1072861. PubMed ID: 36712441
[TBL] [Abstract][Full Text] [Related]
15. Patient-acceptable symptom states in myasthenia gravis.
Mendoza M; Tran C; Bril V; Katzberg HD; Barnett C
Neurology; 2020 Sep; 95(12):e1617-e1628. PubMed ID: 32759200
[TBL] [Abstract][Full Text] [Related]
16. Disease Severity Assessment and Short-Term Outcome in Patients with Myasthenia Gravis.
Vemuri D; Garuda BR; Gopi S; Kumar TS; Kumari UA
Ann Indian Acad Neurol; 2020; 23(2):215-219. PubMed ID: 32189865
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of ocular myasthenia gravis and outcomes of secondary generalisation: a systematic review protocol.
Fang CEH; Bokre D; Wong SH
BMJ Open; 2022 Sep; 12(9):e060259. PubMed ID: 36127086
[TBL] [Abstract][Full Text] [Related]
18. Pediatric Ocular Myasthenia Gravis.
Fisher K; Shah V
Curr Treat Options Neurol; 2019 Sep; 21(10):46. PubMed ID: 31559492
[TBL] [Abstract][Full Text] [Related]
19. The Myasthenia Gravis-specific Activities of Daily Living scale as a useful outcome measure and in routine clinical management in Polish patients.
Rozmilowska IM; Adamczyk-Sowa MH; Czyzewski D
Neurol Neurochir Pol; 2018; 52(3):368-373. PubMed ID: 29370887
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for ocular myasthenia gravis: an observational study in Japan.
Narita T; Nakane S; Nagaishi A; Minami N; Niino M; Kawaguchi N; Murai H; Kira JI; Shimizu J; Iwasa K; Yoshikawa H; Hatanaka Y; Sonoo M; Shimizu Y; Matsuo H
Ther Adv Neurol Disord; 2023; 16():17562864231163819. PubMed ID: 37051222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
